Uses microscopy to view blood vessels in solid tumors
Studies tumor blood vessels in adults with solid tumors using live imaging.
Plain-language title generated from the registry record
Registry title: Intravital Microscopy in Human Solid Tumors
Key facts
- Where
- Jacksonville, United StatesSee the site
Where in United States
- Mayo Clinic FloridaJacksonville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT03823144
- Record updated
- 2 June 2026
- Original description
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. The IVM observations may determine if an individual patient's tumor vessels would be amenable to receiving systemic therapy, based on the functionality of the vessels.Read full original descriptionShow less
Intravital Microscopy (IVM) in Human Solid Tumors
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. The IVM observations may determine if an individual patient's tumor vessels would be amenable to receiving systemic therapy, based on the functionality of the vessels.
Inclusion: Age ≥ 18 years of age; Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2; Measurable tumor by direct visualization requiring surgical resection in the operating room (OR); Tumor types of origin include gastric, pancreatic, hepatobiliary, colorectal, sarcoma, brain, or breast cancer that may involve the axillary lymph nodes cancers. Tumors may be primary or metastatic; Subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent; Subject must have a skin prick test pre-operatively (at the time of the preoperative visit and after signed informed consent for entry into this clinical trial is given) to determine any sensitivity to fluorescein.
Exclusion: Any known allergy or prior reaction to fluorescein or a positive skin prick test to fluorescein; Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations; Any condition which in the investigators' opinion deems the patient unsuitable (e.g., abnormal electrocardiography [EKG], including T wave inversion, elevated T waves, prolonged QRS interval, or conduction blocks) or that requires further work-up (including cardiac echo or stress test); Any condition that excludes surgical resection as the standard of care for the patient; Renal dysfunction as defined as a glomerular filtration rate (GFR) < 45; Liver dysfunction as defined by Child-Pugh score > 5, or liver function test (LFT)'s 1.5 x above normal range; Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy test; Unwilling or unable to follow protocol requirements.